Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D016757 | Death, Sudden, Cardiac NIH | 1.00 |
| D017180 | Tachycardia, Ventricular NIH | 1.00 |
| D013610 | Tachycardia NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0004756 | Ventricular tachycardia HPO | 1.00 |
| HP:0001645 | Sudden cardiac death HPO | 1.00 |
| HP:0001649 | Tachycardia HPO | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001297 | Stroke HPO | 0.25 |
| HP:0001658 | Myocardial infarction HPO | 0.22 |
Navigate: Correlations HPO
There is one clinical trial.
The prevalence and typical patterns of neurological complications in hospitalized COVID-19 patients admitted to the intensive care units of the University Hospital Zurich will be investigated. The impact of neurological complications among COVID-19 patients on mortality, functional outcome, and organizational outcomes will be analyzed.
Description: Determine the prevalence of neurological complications in hospitalized COVID-19 patients admitted to the intensive care unit.
Measure: Prevalence of neurological complications Time: through study completion, on an average of 3 weeksDescription: Examine if empiric COVID-19 therapies are associated with difference in the prevalence and outcome of severe neurological complications of COVID-19.
Measure: Prevalence and outcome of severe neurological complications Time: through study completion, on an average of 3 weeksDescription: Determine the impact of neurological complications among COVID-19 patients on mortality, functional outcome, and organizational outcomes (ICU length of stay, hospital length of stay) among patients with confirmed COVID-19.
Measure: Impact of neurological complications Time: through study completion, on an average of 3 weeksDescription: Analyze characteristic patterns in cerebral imaging and electroencephalography (EEG), as well as cerebrospinal fluid (CSF) of patients, in whom a lumbar puncture has been performed for clinical reasons
Measure: Characteristic patterns in cerebral imaging and electroencephalography (EEG), as well as cerebrospinal fluid (CSF) Time: through study completion, on an average of 3 weeksDescription: Analyze the brain for pathological changes and histopathological findings, if the patient dies.
Measure: Brain for pathological changes and histopathological findings (if patient dies). Time: through study completion, on an average of 3 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports